Ensysce Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on September 27, 2021, regarding events occurring on September 24, 2021. Ensysce Biosciences, Inc. (Ensysce), a Delaware corporation, entered into a Securities Purchase Agreement (SPA) with institutional investors to secure an aggregate financing of $15 million.
Key Financial Metrics and Transaction Details
The filing details a two-closing financing structure involving senior secured convertible promissory notes and warrants:
- Total Financing: $15 million aggregate.
- First Closing (Completed Sept 24, 2021):
- Notes Principal: $5.3 million (Purchase Price: $5 million).
- Warrants Issued: 361,158 shares.
- Second Closing (Conditional):
- Notes Principal: $10.6 million (Purchase Price: $10 million).
- Warrants Issued: 722,317 shares.
- Note Terms: 21-month term, 5.0% annual interest, 6% original issue discount (OID). Convertible at $5.87 per share (30% premium to average price prior to closing).
- Warrant Terms: Exercise price of $7.63 per share; 5-year term.
- Collateral: Notes are secured by all assets of the Company and subsidiaries, including patents.
Material Changes and Obligations
The primary material change is the creation of a direct financial obligation and the issuance of unregistered equity securities. Key obligations include:
- Monthly Redemption: Commencing January 1, 2022, the Company must redeem 92% of the average of the three lowest VWAPs in the prior 10 trading days or pay cash with an 8% premium on 1/18th of the principal plus interest.
- Conversion Option: The Company may elect to pay redemption amounts in conversion shares if the conversion price is at least $0.78 and equity conditions are met.
- Registration Rights: The Company agreed to register the resale of shares issuable upon conversion and warrant exercise. The second closing is contingent on the SEC declaring the registration statement effective.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements subject to risks and uncertainties. Specific contingencies include:
- Second Closing Condition: The remaining $10 million tranche is contingent on the effectiveness of the SEC registration statement (no later than the 2nd trading day after effectiveness).
- Default Triggers: The Notes contain covenants and events of default that could require immediate repayment of obligations.
- Market Risk: Redemption amounts are tied to the Company's stock price (VWAP), creating variable cash or equity outflow requirements.
Investor Verification Checklist
- Verify the status of the SEC registration statement required for the second closing of the $10 million tranche.
- Review the Security Agreement and Patent Security Agreement to understand the scope of assets pledged as collateral.
- Monitor the Company's stock price (VWAP) to assess potential monthly redemption obligations starting January 2022.
- Confirm the number of shares outstanding post-issuance of the initial 361,158 warrants and potential dilution from future conversions.
- Check for any subsequent filings regarding the satisfaction of conditions for the second closing.